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Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways
evidence in SCD patients is lacking. Vancomycin, an antibiotic primarily excreted via glomerular filtration, is commonly used to treat gram-positive pathogens. The drug level is frequently measured to optimize the dosing regimen. 3 We studied vancomycin as a model to
show that patients with SCD had increasing drug dosing requirements. Pathway analysis and gene profiling analysis demonstrated that both hyperfiltration-dependent and independent mechanisms appear to contribute to increased drug clearance in this patient population.
Using a pharmacy order reporting system, we conducted a retrospective cohort study of SCD adults with a creatinine clearance (CrCl) HgbSC and matched controls had 8 subjects in each group, and the comparisons failed to show statistical significance, likely due to the small numbers of subjects.
A linear regression analysis of the vancomycin trough level was performed in a multivariate analysis that adjusted for age, gender, SCD genotype (HgbAA, HgbSC, and HgbSS coded as 0, 1, and 2), and weight-based vancomycin dose. SCD genotype was an independent correlate of lower trough level (β = -0.083, 95% CI: -0.023 to -0.144, p = 0.007; Figure 1a ). We hypothesized that increased renal clearance due to glomerular hyperfiltration could be one of the mechanisms causing the higher dosing requirements in the SCD group. Consistent with our hypothesis, CrCl or eGFR was an independent, significant predictor of the trough level (p < 4 0.001) when added to this model, whereas SCD genotype was less significant (p = 0.036 and p = 0.112, respectively).
We also performed pathway analysis of vancomycin trough level using structural equation modelling. 6 The fitness of the model was jointly determined by the goodness-of-fit test, To explore potential SCD-specific drug metabolism independent of renal clearance, we examined a list of genes involved in drug metabolism (transporters, Phase I and II metabolism enzymes) for enrichment in genes differentially expressed ≥ 1.2 fold change at 5% false discovery rate (Table 2 ). These genes had been identified in a previous study that compared 13 African-American HgbSS patients and 16 African-American HgbAA control individuals, all at steady state. 8 Among the genes interrogated by the Affymatrix Exon array and analyzed previously, 8 genes involved in drug metabolism were enriched by 2.1 fold in the genes 5 differentially expressed in SCD (Chi-squared test, p=0.0032), suggesting that drug metabolismrelated transcription, enriched in hepatocytes, is prone to be altered in SCD.
As SCD is an immunocompromised condition, patients are at an increased risk for developing invasive infections warranting antibiotic treatment 9 and it has been shown that using standard dosing regimens when treating SCD patients with gentamicin leads to sub-optimal drug concentrations. 10 Our results demonstrate that the vancomycin dosing requirement is increased by approximately by 20% (0.043 vs. 0.036 gram/day/kg) in the SCD group to achieve a comparable drug level to non-SCD patients. The majority of vancomycin is excreted unchanged via glomerular filtration, 3 and glomerular hyperfiltration has caused increased vancomycin dosing requirements in other disease states. 2 A limitation to our study is that using CrCl as an estimation of kidney function in patients with SCD may over-estimate the GFR due to reduced muscle mass. 11 In the pathway analysis, we found evidence that SCD contributed to lower vancomycin trough levels via both hyperfiltration-dependent and independent mechanisms. The fitness of the pathway model was best when a hyperfiltration threshold was used instead of CrCl as a linear variable, consistent with hyperfiltration as one mechanism for increased drug clearance. SCD patients have increased hepatic and renal blood flow, and both may contribute to increased clearance of morphine in this patient population. 12 It has been shown that 30% of vancomycin clearance is via a nonrenal mechanism 13 and that the half-life of vancomycin is prolonged in patients with impaired liver function. 14 Although the exact metabolism of vancomycin is still unclear, the non-renal clearance is likely via hepatic conjugation based on the availability of functional groups in the vancomycin molecular structure. 15 In summary, we found that SCD patients with normal kidney function had an approximately 20% higher vancomycin dosing requirement to reach comparable drug levels in 6 non-SCD patients. The higher dosing requirement for vancomycin appears to be in part due to glomerular hyperfiltration and in part due to increased drug metabolism. Despite this finding, we cannot make a blanket recommendation that vancomycin dosing be higher in SCD, anticipating glomerular hyperfiltration, because many SCD patients have chronic kidney disease with low
CrCl and others may experience acute kidney injury during vaso-occlusive pain crisis. 1 Our results do call for especially close monitoring of vancomycin levels and doses in patients with SCD, and they underscore the need to further investigate pharmacokinetics and metabolism of vancomycin and other drugs in this patient population. 
